CRISPR Gene Editing Congress, 25-27 February 2015 in Boston, MA

  • View
    714

  • Download
    1

Embed Size (px)

Transcript

  • 25-27 February 2015 | Boston, USA

    Tel: +1 212 531 5898 | Email: info@hansonwade.com

    RESEARCHED & DEVELOPED BY:

    Unlocking Precision Genome Editing for Therapeutic Development & Biomedical Research Applications

    GEORGE CHURCHHarvard University

    ALEXANDRA GLUCKSMANN Editas Medicine

    ERIC RHODESHorizon Discovery

    KEITH JOUNG Harvard University

    RODGER NOVAKCRISPR Therapeutics

    This is designed to describe the profound impact CRISPR is having on basic research and therapeutic development. It will explore the research tools, bioinformatics and expertise needed to make the most of this breakthrough technology

    Eric Rhodes onCRISPR Congress 2015

    crispr-congress.com

    LEAD PARTNER PROGRAM PARTNERS EXHIBITORHOSTING PARTNER

  • 1 6

    3 8

    2 7

    4 9

    5 10

    BENEFITS OF ATTENDING

    Tel: +1 212 531 5898 Email: info@hansonwade.com

    crispr-congress.com #CRISPR2015 CRISPR Precision Genome Editing

    CRISPR Precision Gene Editing Congress Boston, USA | 25-27 February 2015

    Enhance the Implementation of CRISPR Gene Editing Technology & Advance your Research

    Seize the value of CRISPR/Cas9 gene editing and discover its evolving application in target identification and therapeutic development

    With its ground breaking convenience and simplicity, the emergence of CRISPR genome technology has taken gene editing from a niche pursuit and opened it up to the wider scientific community, in turn revolutionizing and optimizing the application of highly precise genome editing.

    Key industry leaders will gather at the inaugural CRISPR Precision Gene Editing Congress with an ultimate purpose of addressing the importance of overcoming specificity, efficiency and delivery challenges associated

    with the CRISPR/Cas9 system. Furthermore, pioneers will showcase the exploding biomedical and therapeutic potential of gene editing tools for drug discovery and development.

    CRISPR congress brings together those who are striving to unlock the potential and capture the innovative applications of CRISPR technology under one roof.

    Utilize the industrys greatest minds to optimize your gene engineering applications.

    Discover the approaches being applied to overcome CRISPR/Cas9 off-cuts and enhance specificity

    Harness the bioinformatic approach to detect off-cuts and improve CRISPR/Cas9 specificity

    TOP 10 REASONS TO ATTEND CRISPR CONGRESS

    Harness the innovative approaches being utilized to overcome in vivo delivery challenges in the development of disease models

    Explore how CRISPR based functional genomic screening is being applied to improve identification and validation of new drug targets

    Explore how CRISPR technology is being utilized in basic research to enhance your own application of CRISPR gene editing

    Discover how CRISPR technology is being applied to compliment other gene editing tools

    Learn about the application of CRISPR technology in epigenome editing of human cells and stem cell biology

    Harness the high throughout methods being developed for efficient RNA delivery and gene editing

    Enhance your knowledge on key safety issues surrounding the development of CRISPR-based therapeutics

    Learn about the platform advancements required to advance CRISPR technology to the clinic and develop CRISPR-based therapies

  • SPEAKER FACULTY

    Tel: +1 212 531 5898 Email: info@hansonwade.com

    crispr-congress.com #CRISPR2015 CRISPR Precision Genome Editing

    CRISPR Precision Gene Editing Congress Boston, USA | 25-27 February 2015

    Eric RhodesChief Technology OfficerHorizon Discovery

    Katrine BosleyChief Executive Officer Editas Medicine

    Keith JoungAssociate Chief of Pathology for Research and the Jim and Ann Orr MGH Research Scholar, Massachusetts General Hospital; Associate Professor of Pathology, Harvard University

    Alexandra GlucksmannChief Operating OfficerEditas Medicine

    Matthew PorteusAssociate Professor of PaediatricsStanford University

    Charles GersbachAssistant Professor, Biomedical Engineering, Investigator, Center for Genomic and Computational Biology

    Duke University

    Daniel AndersonSam Goldblith Associate ProfessorMassachusetts Institute of Technology (MIT)

    David BumcrotSenior Director, Molecular and Cell BiologyEditas Medicine

    Mark KayProfessor of Pediatrics and GeneticsStanford University

    Yi Yang Senior Research InvestigatorNovartis

    Kiran MusunuruAssistant Professor, Stem Cell and Regenerative BiologyHarvard University

    Stanley QiAssistant Professor, Bioengineering and Chemical and Systems BiologyStanford University

    Gregory DavisR&D Manager, Molecular BiotechnologySigma-Aldrich Corporation

    Jason PotterSenior Scientist in Protein EngineeringThermo Fisher Scientific

    TJ CradickDirector of Protein Engineering FacilityGeorgia Institute of Technology

    David LiuProfessor of Chemistry and Chemical Biology, Howard Hughes Medical Institute InvestigatorHarvard University

    Wenning QinAssociate Director of Genetic Engineering TechnologiesThe Jackson Laboratory

    Richard ChenPrincipal Scientist, Genetics and PharmacogenomicsMerck

    Rodger NovakChief Executive OfficerCRISPR Therapeutics

    Terence FlotteProfessor, Deanand Provost, University of Massachusetts Medical School

    Derrick RossiAssistant Professor, Stem Cell and Regenerative BiologyHarvard University

    Christian MuellerAssistant Professor, PaediatricsUniversity of Massachusetts Medical School

    John FederAssociate Director of Genome BiologyBristol-Myers Squibb

    Hari JayaramSenior ScientistEditas Medicine

    Jochen WelckerSenior Manager Scientific DevelopmentTaconic Biosciences GmbH

    Vittorio SebastianoAssistant Professor of Obstetrics and Gynecology, Director of Human Pluripotent Stem Cells Core Facility and TKTCStanford Cancer Institute

    George ChurchProfessor of GeneticsHarvard Medical School

  • CONFERENCE DAY ONE

    8.00 Registration, Breakfast & Networking

    9.00 Welcome Address from Lead Partner Horizon Discovery Eric Rhodes, Chief Technology Officer, Horizon Discovery

    9.05 Chairs Opening Remarks Alexandra Glucksmann, Chief Operating Officer, Editas Medicine

    9.10 Unlocking Future CRISPR Applications: Conversations That Matter Gain an exclusive insight into the latest developments within the field of CRISPR technology via one-on-one interviews with a panel of key opinion leaders. Join those paving the way in implementing CRISPR technology for therapeutic and biomedical applications, as well as in drug discovery and development. The panel will discuss and answer the following questions:

    Are we in a CRISPR revolution?

    What has been the impact so far and how high can CRISPR reach?

    How can we make this technology better and work harder?

    What are the potential applications of CRISPR in drug discovery and development?

    How is the technology being utilized for gene therapy?

    Moderator: Alexandra Glucksmann, Chief Operating Officer, Editas Medicine

    Keith Joung, Associate Chief of Pathology for Research and the Jim and Ann Orr MGH Research Scholar, Massachusetts General Hospital; Associate Professor of Pathology, Harvard University

    Rodger Novak, Chief Executive Officer, CRISPR Therapeutics

    Charles Gersbach, Assistant Professor, Department of Biomedical Engineering, Investigator, Center for Genomic and Computational Biology, Co-Director, Center for Biomolecular and Tissue Engineering, Duke University

    Katrine Bosley, Chief Executive Officer, Editas Medicine

    10.00 CRISPR and the Rapidly Changing Landscape of Genome Editing Learnings accumulated from over 1 year of industrial application of CRISPR to

    in vitro and in vivo genome editing. Incorporation of CRISPR into products, services and research programs that enable customers engaged at every stage of the healthcare continuum

    Harnessing gene editing of haplogenic cell lines

    A bioinformatics approach for CRISPR experimental design

    Eric Rhodes, Chief Technology Officer, Horizon Discovery

    Horizon welcomes their partners:Tilmann Burckstummer, Director Research and Development, Horizon Genomics GmbH

    Riley Doyle, Chief Executive Officer, Desktop Genetics Ltd

    10.30 Morning Refreshments & Speed Networking

    Harnessing CRISPR Technology for Epigenome Editing

    11.30 Optimizing Technologies for CRISPR-Based Targeted Genome and Epigenome Editing of Human Cells Harness the latest advances in the technologies for highly efficient CRISPR-based

    genome editing of human cells

    Learn about the innovative approaches in CRISPR-mediated epigenome editing of human cells

    Keith Joung, Associate Chief of Pathology for Research and the Jim and Ann Orr MGH Research Scholar, Massachusetts General Hospital; Associate Professor of Pathology, Harvard University

    12.30 Genome and Epigenome Modification with ZFNs and CRISPR/Cas Systems CRISPR nuclease and highly specific paired nickase formats for genome editing in

    animal and plant cells

    Donor DNA formats and their impact on DNA repair rates

    New experimental possibilities using lentiviral delivery of CRISPR elements and CRISPR-based screening

    Zinc finger and CRISPR-mediated epigenetic modifications

    Gregory Davis, R&D Manager, Molecular Biotechnology, Sigma-Aldrich Corporation

    1.00 Networking Lunch & Speakers Corner

    2.00 Epigenome Editing and Controlling Cell Phenotype Utilizing CRISPR/Cas9-based epigenome editors which are exceptionally specific with

    regards to genome-wide DNA-binding, gene regulation, and chromati